Back to news and publications

Strata Oncology Appoints Sundu Brahmasandra as Chief Operating Officer

Experienced diagnostics leader to enhance company’s product development and delivery

March 22, 2022

March 22, 2022

Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced the appointment of Sundu Brahmasandra as Chief Operating Officer. In this role, Brahmasandra will oversee the growth of Strata Oncology’s product development and delivery capabilities. 

“We are excited to welcome Sundu Brahmasandra to the Strata Oncology family. As Chief Operating Officer, Sundu will guide our journey to build and grow the company’s product development and delivery capabilities as we enter a new phase.” said Dan Rhodes, Ph.D., co-founder and Chief Executive Officer, Strata Oncology. “Sundu’s experience building, leading and optimizing successful diagnostics companies will be invaluable to Strata Oncology as we continue growing and providing physicians and oncologists with information that can expand treatment options for patients with cancer.”

Brahmasandra brings to Strata Oncology more than 20 years of technical and operational leadership in the molecular diagnostics field, as well as experience developing industry-leading biotechnology organizations. Before joining Strata Oncology, Brahmasandra served as President and COO of NeuMoDx Molecular, where he was responsible for the design and development of revolutionary molecular diagnostic solutions offering market-leading “sample to result” workflows for central laboratory customers. Sundu oversaw all non-commercial operations, leading the development of scaling up of infrastructure and teams capable of producing over 10 million tests annually. Following the acquisition of NeuMoDx by QIAGEN, Sundu served as the Vice President, Head of Operations and Product Development of QIAGEN’s Ann Arbor operations. Previously, Sundu also served as Vice President, R&D Assay Development at BD Diagnostics, following its acquisition of HandyLab, a developer and manufacturer of molecular diagnostic assays and automation platforms he co-founded. Brahmasandra holds a Ph.D. in chemical engineering from the University of Michigan College of Engineering and a Bachelor of Technology in chemical engineering from the Indian Institute of Technology, Madras.

“Having spent more than two decades in Ann Arbor’s biotech hub, I have the greatest admiration for what Strata Oncology has accomplished to date and am thrilled to be joining at such an exciting phase,” said Brahmasandra. “I look forward to working with this high-caliber team and helping the company navigate a period of high growth to achieve its full potential in helping physicians and patients on the right path to personalized cancer treatment.”

Media Inquiries

Rachel Ford Hutman  rachel@fordhutmanmedia.com 301.801.5540

About Strata Oncology

Strata Oncology, Inc. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer. The company combines molecular profiling, real-world data, and a large-scale clinical trial platform to identify and deliver optimal treatments for patients with cancer. For more information visit strataoncology.com.

In the news

The latest from Strata Oncology

December 1, 2023

Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium

November 8, 2023

Strata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough Awards

September 11, 2023

Dr. Nair on the clinical utility of Immunotherapy Response Score 

September 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

September 7, 2023

Strata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung Cancer

July 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

July 3, 2023

Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

June 14, 2023

Dr Thomas on the Predictive Value of IRS For Pembrolizumab Benefit in Advanced Solid Tumors

June 1, 2023

Evaluation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab (pembro) Clinical Benefit in Patients (pts) with Advanced Solid Tumors

May 2, 2023

Strata Oncology Receives Honorable Mention in Fast Company’s 2023 World Changing Ideas Awards